Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A replication-deficient recombinant lentiviral car-t transgene vector targeting CD123 and its construction method and application

A technology of recombinant lentivirus and transgenic vector, applied in the field of medical biology

Active Publication Date: 2019-03-29
SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is worth noting that the above differences are only the conclusions obtained from in vitro experiments, and there is no report comparing the second-generation and third-generation CARs in vivo.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A replication-deficient recombinant lentiviral car-t transgene vector targeting CD123 and its construction method and application
  • A replication-deficient recombinant lentiviral car-t transgene vector targeting CD123 and its construction method and application
  • A replication-deficient recombinant lentiviral car-t transgene vector targeting CD123 and its construction method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1 Construction of recombinant lentiviral vector

[0068] 1. Materials

[0069] 1. The lentiviral backbone plasmid pLenti-3G ​​basic, the lentiviral packaging plasmids pPac-GP, pPac-R and the membrane protein plasmid pEnv-G, HEK293T / 17 cells, and homologous recombination enzyme were supplied by Shiao (Shanghai) Biomedical Technology Co., Ltd. supply;

[0070] 2. Primers: According to the primer design principles, design the primers required to amplify the DNA fragments and target sites. The primers are synthesized by Shanghai Biological Company, specifically:

[0071] EF1α-F: 5'-ATTCAAAATTTTATCGATGCTCCGGTGCCCGTCAGT-3' (SEQ ID NO.26)

[0072] EF1α-R: 5'-TCACGACACCTGAAATGGAAGA-3' (SEQ ID NO.27)

[0073] CD8leader-F: 5'-GGTGTCGTGAGGATCCGCCACCATGGCCTTACCAGTGACCGC-3' (SEQ ID NO.28)

[0074] CD8leader-R: 5'-GTGTCATCTGGATGTCCGGCCTGGCGGCGTG-3' (SEQ ID NO.29)

[0075] VH-F: 5'-CACGCCGCCAGGCCGGAAGTGAAACTGGTGGAAAGC-3' (SEQ ID NO.30)

[0076] VH-R: 5'-GCTGCTCACGGTCACCA...

Embodiment 2

[0158] Example 2 Concentration and detection of recombinant lentiviral vector

[0159] 1. Purification of recombinant lentiviral vector by ultracentrifugation;

[0160] (1) Divide the collected supernatant into 50ml centrifuge tubes, centrifuge at 500g room temperature for 10min, and remove cells and large debris;

[0161] (2) Filter the supernatant with a 0.22 μm-0.8 μm filter;

[0162] (3) Take 6 Hitachi 40PA ultracentrifuge tubes, spray 70% ethanol on the surface to sterilize them, put them on a clean table and irradiate them with ultraviolet light for 30 minutes to sterilize them. It can also be sterilized by high temperature and moist heat;

[0163] (4) Aliquot 32ml of the cell supernatant sample processed in step 2 into a centrifuge tube;

[0164] (5) Cover the metal cover, balance the centrifuge tube together with the metal cover, and adjust with 1XPBS to make the weight deviation within 0.02g;

[0165] (6) Place the balanced centrifuge tubes symmetrically in the ul...

Embodiment 3

[0242] Example 3 Functional detection of recombinant lentiviral vectors lvCAR123-CLA, lvCAR123-CLB, and lvCAR123-OLC.

[0243] 1. Cell-level expression detection of CAR gene:

[0244] (1) After infecting PBMC cells with recombinant lentiviral vectors lvCAR123-CLA, lvCAR123-CLB, and lvCAR123-OLC, collect the cells and detect CAR mRNA transcription levels by RT-PCR to verify the expression of CAR genes. If the CAR mRNA transcription levels increase, then It shows that the transcription level expression of CAR gene is successful;

[0245] (2) After infecting PBMC cells with recombinant lentiviral vectors lvCAR123-CLA, lvCAR123-CLB, and lvCAR123-OLC, collect the cells and detect the expression level of CAR protein by western blot to verify the expression of CAR gene. If the expression level of CAR protein increases, then It shows that the translation level expression of CAR gene is successful;

[0246] (3) Infect the cells with lvCAR123-CLA, lvCAR123-CLB, lvCAR123-OLC and the co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CD 123-targeting replication-defective recombinant lentivirus CAR-T transgenic vector. The CD 123-targeting replication-defective recombinant lentivirus CAR-T transgenic vector comprises a prokaryotic replicor pUC Ori sequence used for plasmid duplication; an amicillin resistance gene AmpR sequence used for amplification of a large number of target strains; a virus replicor SV40 Ori sequence used for enhancing the replication in eukaryocytes; a lentivirus packaging cis element used for lentivirus packaging; ZsGreen 1 green fluorescent protein used for green fluorescence expression of eukaryocytes; an IRES ribosome binding sequence used for co-transcription and co-expression of protein; a human EF1 alpha promoter used for eukaryotic transcription of genes of a chimeric antigen acceptor; the chimeric antigen acceptor used for forming second-generation CAR or third-generation CAR integrating recognition, delivery and promoting; an eWPRE element used for enhancing the expression efficiency of transgenes. In addition, the invention further discloses a construction method and applications of the vector. With the vector, the secretion of the cell factors and the in-vitro lethal effect of the CAR-T cells can be obviously improved, and the effect in treatingacute myelogenous leukemia (AML) clinically is outstanding.

Description

technical field [0001] The invention belongs to the field of medical biology, and in particular relates to a vector, in particular to a CAR-T transgene vector of a replication-deficient recombinant lentivirus targeting CD123. In addition, the present invention also relates to the construction method and application of the carrier. Background technique [0002] The theoretical basis of tumor immunotherapy is that the immune system has the ability to recognize tumor-associated antigens and regulate the body's ability to attack tumor cells (highly specific cytolysis). This biological process is complex and is still under investigation. In the 1990s, several scientific research groups have discovered tumor antigens (tμmor antigens), and T lymphocytes can recognize these tumor antigens in a major histocompatibility complex (MHC)-dependent manner. [0003] Tumor immunotherapy is generally divided into two categories, nonspecific immunity and specific immunity. Nonspecific immun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/867A61K35/17A61P35/02
CPCA61K35/17C12N15/86C12N2740/15043C12N2800/107
Inventor 祁伟俞磊林高武
Owner SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com